Serum Institute of India applies for full approval of Covishield Covid vaccine

Published on Dec 31, 2021 01:48 PM IST

Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.

Serum Institute, which is also the world's biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.(Reuters)
Serum Institute, which is also the world's biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.(Reuters)
Reuters | , Bengaluru

Serum Institute Of India has applied to the country's drug regulator and the health ministry for full approval of its Covid-19 vaccine Covishield, the company's chief executive said on Friday.

Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.

The Indian government now has enough data to consider a full market authorisation, Serum Institute CEO Adar Poonawalla said on Twitter.

Serum Institute, which is also the world's biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.

The country's inoculation drive so far has been dominated by Covishield and Bharat Biotech's inactivated vaccine Covaxin.

Serum Institute has nearly quadrupled its monthly capacity of AstraZeneca's shots to as many as 240 million doses and is prepared to export "large volumes" from January, Poonawalla told Reuters in October.

Get Latest India Newsalong with Latest Newsand Top Headlinesfrom India and around the world.
SHARE THIS ARTICLE ON
SHARE
Story Saved
OPEN APP
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Thursday, February 09, 2023
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals